<P>Mumbai, Baltimore, April 03, 2019: Pharma major Lupin Limited (Lupin) announced the successful completion of the United States Food and Drug Administration (U.S. FDA) inspection at its Lupin Bioresearch Centre (LBC) without any observations. </P>rnrn<P>This is the fifth successive inspection without any 483 observations, indicating superior quality compliance maintained at this global bioresearch facility. </P>rnrn<P>Lupin Bioresearch Centre (LBC) conducts the in-vivo and in-vitro bioequivalence studies for Lupin in Pune. This inspection also included review of studies done at the center&rsquo;s new site at Lupin Research Park, Pune. </P>rnrn<P>Commenting on the successful inspection, Mr. Nilesh Gupta, Managing Director, Lupin expressed satisfaction about the quality management system maintained in LBC and said “Such a high level of compliance reiterates Lupin&rsquo;s commitment to high-quality standards across its world class research centres.&rdquo; </P&